Hung-Chih Hsu - Search Results

Year	Number of Results
2004	1
2006	1
2007	2
2008	2
2009	3
2010	3
2011	3
2012	5
2013	12
2014	9
2015	4
2016	5
2018	6
2019	4
2020	3
2021	5
2022	5
2023	11
2024	5

1

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.

Hung CL, Liu HH, Fu CW, Yeh HH, Hu TL, Kuo ZK, Lin YC, Jhang MR, Hwang CS, Hsu HC, Kung HJ, Wang LY. Hung CL, et al. Among authors: hsu hc. EBioMedicine. 2023 Apr;90:104500. doi: 10.1016/j.ebiom.2023.104500. Epub 2023 Mar 7. EBioMedicine. 2023. PMID: 36893587 Free PMC article.

2

Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.

Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, Hsu HC, Pao SC, Teng YC, Chen CB, Chao A, Chung WH, Chang JW, Lai CH. Hung SI, et al. Among authors: hsu hc. Biomed Pharmacother. 2023 Dec 31;169:115928. doi: 10.1016/j.biopha.2023.115928. Epub 2023 Nov 26. Biomed Pharmacother. 2023. PMID: 38011788 Free article.

3

Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.

Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Huang WK, et al. Among authors: hsu hc. Eur J Cancer. 2023 Dec;195:113286. doi: 10.1016/j.ejca.2023.113286. Epub 2023 Nov 13. Eur J Cancer. 2023. PMID: 37968194 Clinical Trial.

4

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment.

Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. Chen HH, et al. Among authors: hsu hc. Front Oncol. 2021 Nov 15;11:764912. doi: 10.3389/fonc.2021.764912. eCollection 2021. Front Oncol. 2021. PMID: 34868987 Free PMC article. Review.

5

Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.

Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Huang WK, et al. Among authors: hsu hc. J Am Acad Dermatol. 2024 Feb;90(2):368-369. doi: 10.1016/j.jaad.2023.06.055. Epub 2023 Sep 5. J Am Acad Dermatol. 2024. PMID: 37690021 Clinical Trial. No abstract available.

6

EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response.

Yang CK, Hsu HC, Liu YH, Tsai WS, Ma CP, Chen YT, Tan BC, Lai YY, Chang IY, Yang C, Yang CY, Yu JS, Liu H. Yang CK, et al. Among authors: hsu hc. Cell Oncol (Dordr). 2022 Aug;45(4):621-638. doi: 10.1007/s13402-022-00688-3. Epub 2022 Jul 18. Cell Oncol (Dordr). 2022. PMID: 35849310 Free PMC article.

7

The Longitudinal Trends of Care Needs, Psychological Distress, and Quality of Life and Related Predictors in Taiwanese Colorectal Cancer Survivors.

Wang IY, Jane SW, Hsu HC, Lin YC, Tsai WS, Young CY, Beaton RD, Huang HP. Wang IY, et al. Among authors: hsu hc. Semin Oncol Nurs. 2023 Aug;39(4):151424. doi: 10.1016/j.soncn.2023.151424. Epub 2023 Apr 24. Semin Oncol Nurs. 2023. PMID: 37100635 No abstract available.

8

MicroRNA-based signature for diagnosis and prognosis of colorectal cancer using residuum of fecal immunochemical test.

Chen CC, Chang PY, Chang YS, You JF, Chan EC, Chen JS, Tsai WS, Huang YL, Fan CW, Hsu HC, Chiang JM. Chen CC, et al. Among authors: hsu hc. Biomed J. 2023 Feb;46(1):144-153. doi: 10.1016/j.bj.2022.01.011. Epub 2022 Jan 22. Biomed J. 2023. PMID: 35074584 Free PMC article.

9

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer.

Huang WK, Ho WP, Hsu HC, Chang SH, Chen DY, Chou WC, Chang PH, Chen JS, Yang TS, See LC. Huang WK, et al. Among authors: hsu hc. Front Cardiovasc Med. 2022 Aug 3;9:880956. doi: 10.3389/fcvm.2022.880956. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35990963 Free PMC article.

10

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

Chiang TY, Hsu HC, Chern YJ, Liao CK, Hsu YJ, Tsai WS, Hsieh PS, Lin YF, Lee HL, You JF. Chiang TY, et al. Among authors: hsu hc. Cancers (Basel). 2023 Mar 8;15(6):1663. doi: 10.3390/cancers15061663. Cancers (Basel). 2023. PMID: 36980549 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

82 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year